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Background: Massive industrial production of engineered nanoparticles poses questions about health risks to living
beings. In order to understand the underlying mechanisms, we studied the effects of TiO2 and ZnO agglomerated
engineered nanoparticles (EPs) on erythrocytes, platelet-rich plasma and on suspensions of giant unilamelar
phospholipid vesicles.
Results: Washed erythrocytes, platelet-rich plasma and suspensions of giant unilamelar phospholipid vesicles were
incubated with samples of EPs. These samples were observed by different microscopic techniques. We found that
TiO2 and ZnO EPs adhered to the membrane of washed human and canine erythrocytes. TiO2 and ZnO EPs
induced coalescence of human erythrocytes. Addition of TiO2 and ZnO EPs to platelet-rich plasma caused activation
of human platelets after 24 hours and 3 hours, respectively, while in canine erythrocytes, activation of platelets due
to ZnO EPs occurred already after 1 hour. To assess the effect of EPs on a representative sample of giant unilamelar
phospholipid vesicles, analysis of the recorded populations was improved by applying the principles of statistical
physics. TiO2 EPs did not induce any notable effect on giant unilamelar phospholipid vesicles within 50 minutes of
incubation, while ZnO EPs induced a decrease in the number of giant unilamelar phospholipid vesicles that was
statistically significant (p < 0,001) already after 20 minutes of incubation.
Conclusions: These results indicate that TiO2 and ZnO EPs cause erythrocyte aggregation and could be potentially
prothrombogenic, while ZnO could also cause membrane rupture.
Keywords: Engineered nanoparticles, Erythrocyte shape, Platelet activation, Thrombosis, Cancer, Dog, Phospholipid
vesicles, Biological membrane, Titanium, Zinc oxideBackground
With increasing industrial production of engineered
nano and microparticles, questions have been raised on
their effects on humans and animals [1-4]. Engineered
particles enter the body by inhalation [5], ingestion [6]
and by corrosion of implants [7,8], while possibilities of
injection of engineered nanoparticles for imaging and
therapeutic purposes are being explored [9,10]. In order
to protect ourselves from their (potentially) harmful
effects and use them beneficially, their interactions with* Correspondence: veronika.kralj-iglic@fe.uni-lj.si
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Ljubljana, Ljubljana, Slovenia
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reproduction in any medium, provided the orliving beings should be well studied and the underlying
biochemical and biophysical mechanisms which take
place on the mesoscopic and nanoscopic level [11-17]
should be better understood.
It was observed that engineered nanoparticles can cross
the plasma membrane to be internalized in cells where
they may cause apoptosis [18] and interact with proteins
[19]. It is therefore indicated that studying the interaction
of engineered nanoparticles with membranes [20-22] is
important for the benefit of human and animals. These
studies do not require experiments on laboratory animals
or materials derived from them. Engineered nanoparticle-
membrane interactions can be studied by focusing on
nonspecific biophysical mechanisms that are common inal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and multilamelar lipid vesicles or selected cell models
[20,23,24]. Giant unilamelar phospholipid vesicles lar-
ger than 1 μm (GUVs) [25-28] are a convenient model
system as they can be observed in motion under a light
microscope and enable studies of biological membrane
structure [22], phase behaviour [29,30], permeability
[31,32] and elasticity [33,34], as well as of their interaction
with macromolecules [35]. Another suitable model is
represented by mammalian erythrocytes. Since these cells
lack internal structure, the membrane properties and
interactions are revealed in the change of cell shape which
can be observed under a microscope. There are reports in
the literature that nanoparticles can interact with erythro-
cytes resulting in shape transformations [20,36] and lysis
[37]. Some types of nanoparticles cause formation of re-
active oxygen species [38], induce platelet activation, ag-
gregation and adhesion [39,40], and increase the risk of
thromboembolic disorders [41,42].
In this work we studied the interactions of agglomer-
ated engineered nanoparticles (EPs) with populations of
blood cells and with populations of GUVs. We selected
two different types of EPs that are commonly present in
the environment and have the potential to enter the
body and the circulation system, namely TiO2 and ZnO
EPs.
Results
Figures 1 and 2 show TiO2 and ZnO EPs imaged with
scanning and transmission electron microscopes and their
size distributions, respectively. The populations of TiO2
and ZnO EPs in glucose solution as measured with dy-
namic light scattering (DLS) method were heterogeneousFigure 1 TiO2 and ZnO agglomerated engineered nanoparticles (disso
microscopy (A,C) and by scanning electron microscopy (B,D). Concentin size (Table 1), with large aggregates present in both sus-
pensions tested. DLS measurements of TiO2 and ZnO EP
suspensions in PBS citrate could not be performed due to
strong agglomeration and consequently fast sedimentation
of the EPs.
When dissolved in PBS or glucose, TiO2 EPs and ZnO
EPs were found to be mildly negatively charged as they
displayed negative zeta potentials (Table 1). Measure-
ments of tested suspensions indicated incipient instabil-
ity. ZnO EPs in PBS are the least prone to coalesce
which is in agreement with the measured size of the EPs
(Figure 2, Table 1).
Figure 3 shows the effect of EPs on washed human
erythrocytes as observed by phase contrast optical
microscope. The time of incubation of the erythrocytes
with EPs is indicated in the figure. Incubation with PBS-
citrate showed no effect after 3 hours or after 24 hours
(Figure 3A, B). TiO2 EPs adhered to the erythrocyte
membrane after 3 hours (Figure 3C), while after 24
hours clusters of erythrocytes were formed (Figure 3C).
ZnO EPs showed no effect after 3 hours (Figure 3E),
but after 24 hours clustering of erythrocytes and adhe-
sion of EPs to erythrocytes was observed (Figure 3F).
Figures 4 and 5 show the interaction between EPs and
washed human erythrocytes as observed by scanning
electron microscopy (SEM). TiO2 and ZnO EPs adhered
to the membrane (Figure 4C–F). Singular echinocytes
could be observed in samples treated with EPs
(Figure 5C–F), but not in control samples (A, B).
Figure 6 shows the effect of EPs on platelet-rich
plasma as observed by SEM. Mostly thin disc-like shapes
characteristic of resting platelets can be seen in control
samples and in samples incubated with TiO2 EPs forlved in 0.3M glucose solution) imaged by transmission electron
ration of nanoparticles was 10 μg/ml.
Figure 2 Relative number of agglomerated engineered nanoparticles distributed over size. The height of the column represents the
number of agglomerated engineered nanoparticles pertaining to a given size interval, divided by the number of all agglomerated engineered
nanoparticles measured. Left: the relative number of glucose-suspended TiO2 agglomerated engineered nanoparticles, right: the relative number
of glucose-suspended ZnO agglomerated engineered nanoparticles, as measured by the dynamic light scattering method.
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hours and incubation with ZnO EPs caused transform-
ation to rounded shapes and formation of thin tubular
protrusions characteristic of activated platelets. The ef-
fect was stronger with longer incubation times.
Figure 7 shows washed erythrocytes of a healthy dog
after incubation with PBS-citrate (A), TiO2 EPs (B) and
ZnO EPs (C) for 1 hour as observed by SEM. Echino-
cytes were formed both in control samples and in sam-
ples treated with EPs but we observed no difference in
populations of erythrocytes between the samples. Pores
(marked by an arrow) in the membrane of the untreated
erythrocyte (D) and adhesion of a larger TiO2 aggregate
(E, black arrow) and of numerous ZnO aggregates (F,
white arrow) could be observed. As echinocytic shape of
erythrocytes was present in test samples and in control
sample, it was not ascribed to the effect of EPs.
Figure 8 shows platelet-rich plasma of a healthy dog
after incubation with PBS-citrate (A), TiO2 EPs (B) and
ZnO EPs (C) for 1 hour as observed by SEM. Resting
platelets and singular residual erythrocytes were found
in samples incubated in buffer or in a suspension of
TiO2 EPs. Aggregated TiO2 EPs are visible in the sample
incubated with TiO2 (white arrows, B). Incubation in a
suspension of ZnO EPs caused transformation of disc
shaped platelets into a globular form indicating their ac-
tivation (white arrow, C) while many residual erythro-
cytes (gray arrow, C) could be observed.Table 1 Characteristic properties of population of suspension
Engineered nanoparticles pH Zeta potential [mV]
TiO2 in PBS- citrate 7,9 −26
ZnO in PBS- citrate 7,9 −29
TiO2 in 0,3 M glucose 4,4 −22
ZnO in 0,3 M glucose 6,6 −15
The DLS measurements of TiO2 and ZnO EP suspensions in glucose could be perfor
citrate could not be performed due to fast sedimentation.In experiments with GUVs, a given volume of suspen-
sion containing GUVs was placed on glass slide under
the microscope. After certain time, GUVs in the focal
plane at the bottom of the observation chamber were
counted. If GUVs keep their integrity their number at
the bottom of the chamber increases with time. Namely,
since they contain heavier sugar molecules than the sur-
rounding solution they sediment in the gravitation field.
But if nanoparticles are present in the suspension, some
vesicles are expected to burst. Therefore the test sample
would contain less GUVs than the control sample.
Table 2 shows the average number of GUVs per micro-
graph in test samples and in control samples as observed
after 20 and 50 minutes of incubation. As expected, in
the test and in the control samples the number of
detected GUVs increased with time due to sedimenta-
tion of GUVs. Incubation with TiO2 EPs caused no sig-
nificant effect on vesicle number after 20 or 50 minutes,
i.e. the increase of the number of GUVs in the test and in
the control samples was not statistically significantly differ-
ent after 20 minutes and after 50 minutes. In the samples
exposed to ZnO EPs, a considerable (difference = 17%) and
statistically significant (p < 10-3, P = 0,93) decrease of the
number of GUVs with respect to the control was observed
already after 20 minutes indicating that some GUVs had
bursted. The effect became stronger after 50 minutes. The
difference in number (28%) was statistically very significant
(p < 10-7, P = 1) (Table 2).s of agglomerated engineered nanoparticles
Stability behaviour Size (measured by DLS)
Incipient instability
Incipient instability
Incipient instability 600-4000 nm (average 1820 nm)
Incipient instability 100 – 1200 nm (average 431 nm)
med, but the DLS measurements of TiO2 and ZnO EP suspensions in PBS
Figure 3 Effect of PBS-citrate (control) (A, B), TiO2 (C, D) and ZnO (E, F) agglomerated engineered nanoparticles on populations of
washed human erythrocytes as observed by phase contrast optical microscopy. Agglomerated engineered nanoparticles were suspended
in phosphate buffer saline.
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We studied the effect of TiO2 and ZnO EPs on washed
human and canine erythrocytes, platelet-rich plasma and
on GUVs. We found that both TiO2 and ZnO EPs
caused coalescence of erythrocytes and activation of pla-
telets, while ZnO EPs also caused bursting of GUVs. We
found the effect of both kinds of EPs on the shape of
washed erythrocytes in man and in the dog to be minor;
in humans, EPs induced a change of shape towards
echinocytes in only a small number of erythrocytes
(Figure 5), while in the dog, echinocytosis was also
present in samples of washed erythrocytes incubated
with buffer and was therefore not ascribed to the effect
of EPs (Figure 7).
The effects of EPs on washed human and canine ery-
throcytes and platelet-rich plasma were qualitatively the
same but quantitative differences could be observed. In
the dog, activation of platelets took place after only 1
hour of incubation of platelet-rich plasma with ZnO
EPs, while in man, this effect was observed after 3 hours.
Activation of platelets was also observed in samples
incubated with TiO2 EPs (after 24 hours in man). In the
dog, we did not incubate blood for more than one hour,which could be the reason why no effect of TiO2 EPs on
canine platelets was observed. As some effects of engi-
neered nanoparticles are different in different species it
is indicated that experiments on other species cannot
give information relevant for humans as regards quanti-
tative limits. In vitro methods are suitable for testing the
potentially harmful effects of new materials such as engi-
neered nanoparticles since they address basic mechan-
isms underlying these effects [43].
Experiments with artificial membranes and selected
cell types such as blood cells reveal general mechanisms
that take place in all cells, it is however yet unclear how
likely the studied situation will occur in a cell. Suspen-
sions of GUVs are relatively well controlled but the bio-
logical relevance of the conclusions is limited due to the
simplicity of the system. On the other hand, platelet-rich
plasma better represents the natural system in blood
where complex interactions between engineered nano-
particles and plasma constituents take place.
Alterations in the nanoparticles' environment lead to
their assembly into aggregates and agglomerates. This
could significantly change their biological impact, so the
appropriate characterization of nanoparticles is vital for
Figure 4 Effect of PBS-citrate (control) (A, B), TiO2 (C, D) and ZnO (E, F) agglomerated engineered nanoparticles on washed human
erythrocytes as observed by scanning electron microscopy. Agglomerated engineered nanoparticles were suspended in phosphate buffer
saline. Arrows point to very large agglomerates of nanoparticles.
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fore in studies of the biological reactivity of nanoparti-
cles, their primary characteristics (characteristics of
individual particles) and their secondary characteristics
(characteristics of aggregates and agglomerates) should
be taken into account [44].
Larger EPs were observed to interact with the membranes
of washed erythrocytes (Figure 4C–F, Figure 7E). If the same
particle interacts with the membranes of two cells it
can mediate attractive interaction between the erythrocytes
by a bridging interaction. However, besides very large EPs
(such as the one shown in Figure 4C–F, Figure 7E), the so-
lution contains EPs with a heterogeneous size distribution.
Smaller EPs may induce attractive interaction between
membranes even without strong binding to the membrane.
A possible mechanism of mediating attractive interaction
between membranes derives from the spatial distribution of
charge within the mediating particles. Plasma proteins bind
to EPs [19] which may affect the interaction of EPs with
cells. Also EP-protein complexes may have an internal
charge distribution which differs considerably from the dis-
tribution within bare EPs. In general, the structure of
phospholipid headgroups is multipolar, so the headgroupinterface is a source of electric field. Rearrangement of ions
in solution in the vicinity of the interface screens the field
and creates a gradient [45] in which particles with internal
distribution of charge are free to distribute so as to minimize
their free energy [46]. This effect is especially energetically
favourable when the mediating particles are orientationally
ordered between two interacting membranes separated by a
small distance (of the order of nanometers) while it is
stronger if the charges within the particles are sepa-
rated by a larger distance [47]. The equilibrium config-
uration of membranes and mediating molecules appears
as adhesion between membranes.
Plasma contains proteins that mediate attractive inter-
action between membranes [47-50]. EPs may enhance
the mediating effect of proteins by forming protein-EP
complexes with extended charge distribution and expos-
ure of positively charged domains that favour interaction
with the negatively charged glycolipid coat of the
erythrocyte membrane.
We did not observe adhesion of EPs on platelets, even
though the effect of engineered nanoparticles on plate-
lets induced an activation which is functionally import-
ant. It is possible that EPs undergo changes during the
Figure 5 Effect of PBS-citrate (control) (A, B), TiO2 (C, D) and ZnO (E, F) agglomerated engineered nanoparticles on populations of
washed human erythrocytes as observed by scanning electron microscopy. Agglomerated engineered nanoparticles were suspended in
phosphate buffer saline.
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and releasing ions into the solution. This influences the
osmotic equilibrium, pH equilibrium, screening of the
electric field created by charged species and induces
chemical changes such as formation of deleterious oxi-
dised species. Divalent ions were found to activate plate-
let aggregation as the addition of their chelators EDTA
and citrate inhibits their effect [51]. Ions of transition
elements (Ni, Zn and Mn) cause even faster platelet ag-
gregation than ions of alkaline earth metals (Mg and Ca)
[52]. Zn ions can activate protein kinase C and enhance
fibrinogen receptor exposure on the surface of platelets
stimulated by ADP [53].
On interaction of EPs with the erythrocyte membrane,
we observed no perturbation of the membrane curvature
due to the adhesion of EPs (Figure 4C–F). However, we
observed defects (pores) in the membrane of untreated
canine erythrocytes (Figure 7D) and platelets (not shown)
which seem large enough to facilitate transmembrane
transport of nano-sized (but not micro-sized) EPs. This is
in agreement with previous results [21] where it was
reported that agglomerates larger than 0,2 μm were found
attached to the erythrocyte membrane, whereas smalleraggregates and single particles were found within cells. It
was suggested that neither endocytosis which is based on
vesicle formation, nor any actin-based mechanisms are
likely to account for nanoparticle translocation into
the cell [21] but that smaller EPs probably cross the
membrane through pores or ion channels [54]. This is
in agreement with our observations that no ghosts or
haemoglobin-depleted erythrocytes were seen in the
erythrocyte samples.
The effects of EPs on GUVs are important for under-
standing the potential effects of EPs on biological mem-
branes as phospholipid bilayer is a backbone of the
biological membrane. Limited biological relevance of the
results of experiments with GUVs (due to simplicity of
the system) does not mean that these results have no
value for understanding effects on biological mem-
branes. It is indicated that ZnO (but not TiO2) can cause
rupture of the membrane if it can get close to the
phospholipid bilayer (Table 2). In biological membrane
such situations can be created for example in membrane
budding where lateral redistribution of membrane con-
stituents takes place [55]. Molecules in the outer mem-
brane layer that act as spacers and prevent adhesion of
Figure 6 Effect of PBS-citrate (control) (A-C), TiO2 (D-F) and ZnO (G-I) agglomerated engineered nanoparticles on human platelet rich
plasma as observed by scanning electron microscopy. Samples were incubated with agglomerated engineered nanoparticles dissolved in
phosphate buffer saline for 1 hour (A,D, G), 3 hours (B, E, H) and 24 hours (C, F, I).
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forms between the mother cell and the bud. Namely in
the neck the curvature of the membrane is negative
which is unfavorable for molecules with substantial parts
protruding into the external solution.
The basic paradigm of toxicology indicates that the ef-
fect of the substance is dose dependent. However, this
paradigm is only partly relevant for nanoparticles. Instead,
nanoparticles follow a nano-specific mode of action which
is not yet completely understood. The behaviour of nano-
particles in liquid media is poorly predicted due to the fact
that they aggregate and agglomerate already in exposure
to media as well as when they enter a biological system.
Some authors report that suspensions of nanoparticles
with higher concentrations contain larger aggregates and
thus exhibit lower toxic potential ([56] and references
therein). In addition, aggregates adhere to surfaces outside
or inside organisms and may therefore cause effects with-
out even entering cells. Up to now, no unified directions
exist how to test the effects of nanoparticles and how to
use the data in human or environmental risk assessment.
It is generally accepted that the toxicological tests that are
used to assess the toxicity of non-nanosized substances
should be modified.Conclusions
We found that addition of TiO2 and ZnO EPs to erythro-
cytes suspended in PBS-citrate caused adhesion of EPs tothe membranes of erythrocytes and erythrocyte coales-
cence. Addition of TiO2 and ZnO EPs induced activation
of platelets. This indicates that EPs could be potentially
prothrombogenic. ZnO (but not TiO2) EPs suspended in
glucose solution caused a significant decrease of GUVs in-
dicating that ZnO EPs (but not TiO2 EPs) could cause
membrane rupture. Blood cells and phospholipid vesicles
are convenient systems for the study of membrane proper-
ties and their interactions with various substances. As
knowledge on the relevant mechanisms is as yet rudimen-





choline (POPC) and cholesterol were purchased from Avanti
Polar Lipids, Inc. (Alabaster, Al, USA). Sucrose and glucose
were purchased from Sigma–Aldrich (Steinheim, Germany).
Engineered particles
Titanium (IV) oxide nanopowder (TiO2), supplied as a
powder of anatase crystalline structure, with guaranteed
99,7% purity, and zinc oxide nanopowder (ZnO) were
purchased from Sigma Aldrich (Steinheim, Germany).
Preparation of engineered particle suspensions
For experiments with washed erythrocytes or platelet-
rich plasma, stock suspensions of EPs were prepared in
Figure 7 Effect of PBS-citrate (control), TiO2 and ZnO agglomerated engineered nanoparticles on washed canine erythrocytes. Effect of
PBS-citrate (control) (A), TiO2 (B) and ZnO (C) agglomerated engineered nanoparticles on populations of washed canine erythrocytes. An
erythrocyte with pores (pores are marked by black arrows) in an untreated sample (D). Binding of agglomerates to washed canine erythrocytes:
large TiO2 agglomerate (marked by a black arrow) (E) and numerous ZnO aggregates on the surface of echinocyte (marked by a white arrow) (F).
Agglomerated engineered nanoparticles were suspended in phosphate buffer saline.
Šimundić et al. BMC Veterinary Research 2013, 9:7 Page 9 of 13
http://www.biomedcentral.com/1746-6148/9/7phosphate buffer saline with trisodium citrate (PBS –citrate:
137 mM NaCl, 2,7mM KCl, 10 mM Na2HPO4x2H2O, 2
mM KH2PO4, 10,9 mM Na3C6H5O7) with a concentration
of 5 mg/ml. For experiments with GUVs, stock suspensions
of TiO2 and ZnO EPs were prepared in 0,3 M glucose with
a concentration of 1 mg/ml.
Characterization and imaging of engineered particle
suspensions
Characterization of EPs (primary characteristics of EPs)
and their suspensions (secondary characteristics of EPs)Figure 8 Effect of PBS-citrate (control) (A), TiO2 (B) and ZnO (C) agglo
Platelet-rich plasma was incubated with agglomerated engineered nanopa
Activated platelets (white arrow) and larger number of erythrocytes (gray a
ZnO (C).were assessed by scanning and transmission electron mi-
croscopy (SEM and TEM, respectively), dynamic light
scattering (DLS) and zeta potential (ζ) measurements.
For TEM, water suspension of EPs was applied on a
copper-grid-supported, perforated, transparent carbon
foil at room temperature. TEM imaging of EPs was
performed using a JEOL 2100 transmission electron
microscope (Tokyo, Japan) operated at 200 kV. SEM
imaging of EPs in PBS-citrate was performed using a
LEO Gemini 1530 (LEO, Oberkochen, Germany) scan-
ning electron microscope.merated engineered nanoparticles on canine platelet-rich plasma.
rticles dissolved in phosphate buffer saline for 1 hour.
rrow) including echinocytes can be seen in the sample incubated with
Table 2 Effect of TiO2 and ZnO agglomerated engineered nanoparticles EPs on the average number of giant
unilamelar phospholipid vesicles (GUVs) per micrograph
EPs t[min] GUVs Ntest ± SD GUVs Ncontrol ± SD Micrographs Mtest Micrographs Mcontrol Difference in N p P(α = 0,05)
TiO2 20 8,6 ± 3,6 8,7 ± 3,8 151 151 −1% 0,913 0,03
50 13,4 ± 5,8 14,8 ± 7,0 155 148 −10% 0,465 0,51
ZnO 20 5,2 ± 2,3 6,3 ± 2,8 156 145 −17% 3.10-4* 0,93*
50 6,5 ± 3,5 9,1 ± 4,3 155 144 −28% 3.10-8* 1,00*
The table shows the time of incubation (t), the average number of GUVs per micrograph of the test and of the control suspensions (Ntest and Ncontrol, respectively)
with their standard deviations (SD), the number of harvested micrographs of the test and of the control suspensions (Mtest and Mcontrol, respectively), the
difference between the number of GUVs in the test and in the control suspensions, the statistical significance (p value) of the t-test subject to the difference
between the test and the control suspensions, and the corresponding statistical power P at α = 0,05. Asterisks denote that the difference is statistically significant
and of sufficient power.
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(10 μg/ml) were inspected by DLS using a 3D DLS-SLS
spectrometer (LS Instruments, Fribourg, Switzerland).
Due to very fast sedimentation of both TiO2 and ZnO
EPs, DLS measurements in PBS could not be performed.
The zeta potential (ζ) of TiO2 and ZnO EPs suspensions
in both media, PBS-citrate and in 0,3 M glucose, were
measured at the original concentrations and the pH
values of the suspensions using a ZetaPals instrument
(Brookhaven Instruments Corporation, Holtsville, NY,
USA).
Blood sampling
Blood was collected from the authors and from 3 healthy
pet dogs owned by members of the staff of Prva K Kli-
nika za male živali d.o.o. Ljubljana. 2,7 ml tubes contain-
ing 270 μl trisodium citrate at a concentration 0,109
mol/l were used. All the dogs weighed over 15 kg so the
volume of the blood sample (2,7 ml) was small com-
pared to the whole volume of the animal. Blood was col-
lected by vein puncture into evacuated tubes (BD
Vacutainers, Becton Dickinson, CA) using a 21-gauge
needle (length 70 mm, inner radius 0,4 mm) (Micro-
lance, Becton Dickinson, NJ, USA). Sampling was per-
formed according to the Declaration of Helsinki.
Informed consent was obtained from all human partici-
pants in this study and written consent to take blood
from the dogs was obtained from their owners. The
study as regarding both human and animal samples was
approved by the Slovenian National Medical Ethics Com-
mittee, No 117/02/10. No adverse effects on human and
animal donors’ health due to sampling were observed.
Preparation of blood cells for microscopy
Blood was processed within 1 hour of sampling. Blood
was centrifuged in a Centric 400R centrifuge (Domel
d.o.o., Železniki, Slovenia) at 150 g and 37°C for 10 min-
utes (human) and at 50 g and 37°C for 15 minutes (dog)
to separate erythrocytes from platelet-rich plasma. Ery-
throcytes were repeatedly washed with PBS citrate by
centrifugation at 1550 g and 37°C for 10 minutes.Washed erythrocytes or platelet-rich plasma were ali-
quotted into equal parts (50 μl in case of erythrocytes
and 200 μl in case of platelet-rich plasma). TiO2 or ZnO
EPs suspended in PBS-citrate (or PBS-citrate alone for
the control) was added to aliquot in a v/v ratio of 2:1 in
the case of erythrocytes and 3:1 in the case of platelet-
rich plasma, 3 and 2 units corresponding to erythrocytes
and platelet-rich plasma, respectively. After incubation
the samples were fixed in 0,1% glutaraldehyde, incubated
for another hour at room temperature and centrifuged
at 1550 g and 37°C for 10 minutes. The supernatant was
exchanged with PBS-citrate, samples were vortexed, cen-
trifuged at 1550 g and 37°C for 10 minutes and fixed in
2% glutaraldehyde for an hour.
Phase contrast microscopy of erythrocytes
5 μl of erythrocyte suspension was placed in an observa-
tion chamber composed of two cover glasses which were
glued together with nail polish. Samples were observed
under an Olympus GWB BH-2 (Olympus Corporation,
Tokyo, Japan) microscope with phase contrast optics at
an objective magnification of 400×. Images were taken
with a Canon EOS 450D digital camera (Canon Inc.,
Tokyo, Japan).
Scanning electron microscopy of blood cells
Fixed samples were washed by exchanging supernatant
with citrated PBS and incubated for 20 minutes at room
temperature. This procedure was repeated 4 times while
the last incubation was performed overnight at 8°C.
Samples were then post-fixed for 60 min at 22°C in 1%
OsO4 dissolved in 0,9% NaCl, dehydrated in a graded
series of acetone/water (50%-100%, v/v), critical-point
dried, gold-sputtered, and examined using a LEO
Gemini 1530 (LEO, Oberkochen, Germany) scanning
electron microscope.
Preparation of giant unilamelar phospholipid vesicles
The electroformation of GUVs was performed at room
temperature. 40 μl of the lipid mixture of POPC (80%, v/v)
and cholesterol (20%, v/v), both dissolved in 2:1
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inum electrodes and the solvent was allowed to evapor-
ate in low vacuum for two hours. The electrodes were
then placed in the electroformation chamber (a 2 ml
Eppendorf cup), filled with 2 ml of 0,3 M sucrose solution.
An alternating electric field was applied as described in
[55]. After electroformation, 600 μl of 0,3M sucrose solu-
tion containing GUVs was added to 1 ml of 0,3M glucose
solution.
Experiments with giant unilamelar phospholipid vesicles
and engineered particles
Experiments with the two types of EPs, TiO2 and ZnO,
were performed separately, but following the same pro-
cedure. After electroformation, the suspension of GUVs
in sucrose/glucose solution was mixed by turning the
Eppendorf cup upside down (five times). The suspension
was diluted (300 μl of 0,3M glucose solution was added
to 100 μl of original vesicle solution) in order to obtain
the desired concentration of GUVs, which was found
convenient according to preliminary experiments. Subse-
quently, the diluted suspension was aliquotted into 4
vials, (81 μl in each vial). Duplicates of test suspension
of EPs (TiO2 or ZnO, both dissolved in 0,3M glucose so-
lution with a concentration of 100 μg/ml) and duplicates
of control suspension (0,3M glucose solution) were
added to GUV suspensions in a volume ratio of 9:1
(GUVs: test suspension) to reach the final concentration
of EPs of 10 μg/ml. Vials were turned upside down five
times to mix the test suspension with the GUV suspen-
sion. The samples (70 μl each) were separately trans-
ferred into four CoverWellTM Perfusion chambers
PC4L-0,5 (Grace Bio-Labs Sigma-Aldrich, Steinheim,
Germany) to create duplicates for the test sample and
duplicates for the control sample.
The observation chambers with samples were mounted
to the inverted phase contrast light microscope (Nikon
Eclipse TE2000-S, Tokyo, Japan). After pre-defined dura-
tions of incubation (20 and 50 minutes), GUV populations
in each chamber were recorded by a Sony CCD video
camera module, model: XC -77 CE (Minato, Japan). These
recordings consisted of two video sequences each approxi-
mately 2 minutes long. During recording, the object glass
was moved to capture images of thousands of GUVs.
Using image processing algorithms, the video sequences
were transformed into large mosaics [57] where each mo-
saic contained all the vesicles acquired within the sample.
GUVs in mosaics were segmented using a computer-aided
approach [58].
Statistical analysis
Here we introduced improvements to the analysis of
GUV populations. The mosaics were separated into
images (micrographs) with the size of a single field ofview with the microscope at a given magnification. Using
the GUVs’ locations inside the mosaics, all vesicles were
associated with the appropriate micrograph, allowing us
to extract information on vesicle density throughout the
micrographs composing the mosaic.
The numbers of GUVs in a micrograph were averaged
over all micrographs within the test and control samples.
Methods of descriptive statistics were used to compare
the test samples and the respective control samples. We
used a two-sided pooled t-test with equal variance. A
probability of the t-test below 0,05 was considered statis-
tically significant. Power analysis was performed in order
to validate the size of the samples. A power larger than
0,9 at α = 0.05 indicated a sample of proper size. The
software used for statistical analysis was from R Devel-
opment Core Team: R: A language and environment for
statistical computing. R Foundation for Statistical Com-
puting, Vienna, Austria. 2008 ISBN 3-900051-07-0, URL
http://www.R-project.org.
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